Welcome to the RKIP and YY1 Symposium 2023 in Catania, Sicily (Italy)
It is our great pleasure to invite you to join the 1st Joint International Symposium on “Prognostic and Therapeutic implications of RKIP and YY1 in Cancer, Diabetes and Cardiovascular Diseases” which will be held in Italy in the beautiful city of Catania, Sicily, March 8-11, 2023.
Cancer, heart disease and diabetes are leading causes of morbidity and mortality worldwide, while recent reports are underlying common molecular cascades involved in their pathogeneses. In this context, the symposium is focused on the recent advances reported on two pivotal gene products, namely, Raf-1 kinase inhibitory protein (RKIP) and Yin Yang 1(YY1) whose levels of expression contribute in the pathogenesis of cancer, diabetes and cardiovascular diseases. Thus, both RKIP and YY1 are potential therapeutic targets in the treatment of these various diseases.
Following the tradition of previous meetings, a great deal of thought went into formulating a stimulating scientific program prepared for you by our Scientific Committee, offering the opportunity to meet with colleagues and experience the wonderful hospitality and scenery of Catania, Sicily (Italy).
Massimo Libra, University of Catania, Italy; email: email@example.com (local organizer);
Fahd Al-Mulla, Kuwait University, Kuwait; email: firstname.lastname@example.org;
Benjamin Bonavida, UCLA, Los Angeles, USA; email: BBonavida@mednet.ucla.edu;
Stavroula Baritaki, Crete University, Grrece; email: email@example.com;
Marsha Rosner, University of Chicago, USA; email: firstname.lastname@example.org
Kam C. Yeung, University of Toledo, USA; email: email@example.com
Call for Abstract
Invited Speakers/Participants are invited to submit the abstracts by December 31st, 2022 according to the following instructions and within the format that you find in the ABSTRACT LINK
Abstracts are to be written in English and not exceed 800 words (space excluded).
Abstract includes Title (Font: bold; Size: 14); Authors (Font normal; Size: 12); Affiliations (Font normal; Size: 10). The author presenter font should be bold. The Abstract title should clearly define the work discussed. The main text of the abstract should be dived in the following sections: Rational, Hypothesis, Aim, Results and Discussion. Abbreviations must be spelled out in full at their first use.
Abstract must be sent through the following link. For not invited speakers, if the contribution is accepted as brief communication or poster presentation they will be notified by e-mail by January 15th, 2023.